Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Study of PK/PD, Safety and Tolerability of LIK066 in Patients With Decreased Renal Function.

Phase 2

Completed

Conditions: Renal Impairment

Interventions: Drug: LIK066

First Posted Date: 2017-04-27

Last Posted Date: 2021-01-05

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 53

Registration Number: NCT03131479

Locations: 🇺🇸
Novartis Investigative Site, Orlando, Florida, United States

A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease

Phase 2

Terminated

Conditions: Alzheimers Disease

Interventions: Drug: CNP520 50mg
Drug: CNP520 15mg
Other: Matching placebo

First Posted Date: 2017-04-27

Last Posted Date: 2021-08-05

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 1145

Registration Number: NCT03131453

Locations: 🇺🇸
Meridien Research, 2300 Maitland center, Pkwy Ste 230, Maitland, Florida, United States
🇺🇸
Syrentis Clinical Research, 1401 N Tustin Ave, Suite 130, Santa Ana, California, United States
🇬🇧
Novartis Investigative Site, London, United Kingdom

and more 33 locations

Phase III B in Acute Lymphoblastic Leukemia

Phase 3

Completed

Conditions: Acute Lymphoblastic Leukemia

Interventions: Biological: CTL019

First Posted Date: 2017-04-21

Last Posted Date: 2021-07-21

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 69

Registration Number: NCT03123939

Locations: 🇪🇸
Novartis Investigative Site, Esplugues de Llobregat, Barcelona, Spain

Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors

Phase 1

Active, not recruiting

Conditions: Advanced EGFR Mutant Non Small Cell LungCancer (NSCLC)
KRAS G12-mutant NSCLC
Esophageal Squamous Cell Cancer (SCC)
Head/Neck SCC
Melanoma
Advanced Gastrointestinal Stromal Tumors (GIST)
Advanced NRAS/BRAFT wt Cutaneous Melanoma

Interventions: Drug: TNO155
Drug: TNO155 in combination with EGF816 (nazartinib)

First Posted Date: 2017-04-14

Last Posted Date: 2025-05-29

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 227

Registration Number: NCT03114319

Locations: 🇺🇸
H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
🇺🇸
Dana Farber Cancer Center, Boston, Massachusetts, United States
🇺🇸
Memorial Sloane Ketterin Cancer Ctr, New York, New York, United States

and more 2 locations

An Expanded Treatment Protocol (ETP) of Midostaurin (PKC412) in Patients 18 Years of Age or Older With Newly-diagnosed FLT3-mutated Acute Myeloid Leukemia (AML)

Conditions: FLT3-mutated Acute Myeloid Leukemia

First Posted Date: 2017-04-14

Last Posted Date: 2019-10-15

Lead Sponsor: Novartis Pharmaceuticals

Registration Number: NCT03114228

Locations: 🇨🇦
Novartis Investigative Site, Montreal, Quebec, Canada

Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Multiple Myeloma

Phase 1

Completed

Conditions: Multiple Myeloma

Interventions: Drug: PDR001
Drug: CJM112
Drug: LCL161

First Posted Date: 2017-04-13

Last Posted Date: 2022-02-09

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 26

Registration Number: NCT03111992

Locations: 🇺🇸
Mayo Clinic Arizona, Phoenix, Arizona, United States
🇺🇸
Sarah Cannon Research Institute, Nashville, Tennessee, United States
🇪🇸
Novartis Investigative Site, Madrid, Spain

Assess Bronchodilator Effect QVM149 Dosed Either in the Morning or Evening Compared to Placebo in Patients With Asthma

Phase 2

Completed

Conditions: Asthma

First Posted Date: 2017-04-11

Last Posted Date: 2021-01-05

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 38

Registration Number: NCT03108027

Locations: 🇬🇧
Novartis Investigative Site, Machester, United Kingdom

Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs

Phase 3

Completed

Conditions: Chronic Myelogenous Leukemia

Interventions: Drug: Asciminib
Drug: Bosutinib

First Posted Date: 2017-04-10

Last Posted Date: 2025-04-08

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 233

Registration Number: NCT03106779

Locations: 🇺🇸
Dana Farber Cancer Center, Boston, Massachusetts, United States
🇺🇸
University of Michigan Clinical Trials Office, Ann Arbor, Michigan, United States
🇺🇸
Utah Huntsman Cancer Center, Salt Lake City, Utah, United States

and more 8 locations

A Study to Evaluate the Change in Weight After 24 Weeks Treatment With LIK066 in Obese or Overweight Adults

Phase 2

Completed

Conditions: Obesity
Overweight

Interventions: Drug: Placebo
Drug: LIK066

First Posted Date: 2017-04-04

Last Posted Date: 2020-02-06

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 460

Registration Number: NCT03100058

Locations: 🇬🇧
Novartis Investigative Site, Stevenage, United Kingdom

A Long-term Safety Study of QMF149 in Japanese Participants With Asthma

Phase 3

Completed

Conditions: Asthma

Interventions: Drug: QMF149

First Posted Date: 2017-04-04

Last Posted Date: 2020-02-07

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 51

Registration Number: NCT03100500

Locations: 🇯🇵
Novartis Investigative Site, Toshima-ku, Tokyo, Japan

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy